Form 4: Scholar Rock Director Exercises Options and Sells Shares Under Pre-Arranged 10b5-1 Plan

Jeffrey S. Flier, a Director at Scholar Rock Holding Corp, executed a series of transactions on June 23, 2025, involving the exercise of stock options and subsequent sale of common stock, all conducted under a Rule 10b5-1 trading plan.

Summary

• Jeffrey S. Flier, a Director of Scholar Rock Holding Corp (SRRK), completed multiple transactions on June 23, 2025.
• He exercised stock options to acquire 20,316 shares of common stock at an exercise price of $21.62 per share.
• Following the option exercise, Mr. Flier sold a total of 31,452 shares of common stock in three separate transactions.
• The sales were executed at weighted average prices of $32.1571 for 17,550 shares, $32.7358 for 2,766 shares, and $33.2092 for 11,136 shares.
• These transactions were pre-arranged and conducted pursuant to a Rule 10b5-1 trading plan, which was adopted on February 27, 2025.
• After these transactions, Mr. Flier's direct beneficial ownership of Scholar Rock common stock is 0 shares.
• He indirectly beneficially owns 11,136 shares through The Jeffrey S. Flier Family Trust 2014, for which he disclaims Section 16 beneficial ownership.
• The shares beneficially owned directly after the exercise consisted of 36,754 common stock and 7,632 restricted stock units (RSUs).
• After the first sale, direct beneficial ownership was 19,204 common stock and 7,632 RSUs.
• After the second sale, direct beneficial ownership was 16,438 common stock and 7,632 RSUs.
• The stock option exercised had no unvested shares remaining.

Sentiment

Score: 5

Explanation: A score of 5 indicates a neutral sentiment. While insider selling can sometimes be viewed negatively, the fact that these transactions were conducted under a pre-arranged Rule 10b5-1 plan mitigates concerns about opportunistic trading based on new negative information. It's a routine liquidity event for an insider.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and transparent sale not based on immediate insider information.
• The sale prices ($32.1571, $32.7358, $33.2092) are significantly higher than the exercise price ($21.62), indicating a profitable transaction for the insider.

Negatives

• A director selling a substantial number of shares (31,452 shares) could be perceived negatively by the market, potentially signaling a lack of confidence, although this is mitigated by the 10b5-1 plan.
• The reduction of direct beneficial ownership to zero, with remaining shares held indirectly by a trust for which ownership is disclaimed, might be seen as a further reduction in direct alignment with shareholders.

Risks

• Potential for negative market perception due to insider selling, despite the transparency offered by the Rule 10b5-1 plan.
• The disclaimer of beneficial ownership for shares held by the family trust could reduce the perceived alignment of the director's personal financial interests with the company's stock performance.

Future Outlook

This Form 4 filing reports past insider transactions and does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Management Comments

• The filing notes that the sales were effected pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2025.
• The Reporting Person disclaims Section 16 beneficial ownership of the securities held by The Jeffrey S. Flier Family Trust 2014.

Industry Context

Insider transactions, particularly sales by directors, are common in the biotechnology and pharmaceutical sectors, often related to liquidity needs, diversification, or the exercise and sale of vested equity compensation. The use of a Rule 10b5-1 plan is a standard practice for insiders to manage such transactions in compliance with insider trading regulations, providing a defense against claims of trading on material non-public information.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan for insider sales is a widely accepted corporate governance practice, aligning with industry standards for transparency and compliance.
• Many executives and directors across various industries, including biotech, utilize such plans to manage their equity holdings in a pre-scheduled and compliant manner.
• The specific prices and volumes are unique to this transaction and company, but the mechanism of sale is standard for insider liquidity events.

Stakeholder Impact

• Shareholders: May interpret the director's sale as a signal, though the 10b5-1 plan suggests it's a planned liquidity event rather than a reaction to new information. The reduction in direct ownership might slightly reduce perceived alignment.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The document does not specify any future actions or milestones for the company or the reporting person beyond the completion of these transactions.

Key Dates

Recommendation

Keywords

Scholar Rock Holding Corp, SRRK, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Rule 10b5-1 Plan, Director Transactions, Biotechnology, Pharmaceuticals